Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07111247 · ClinicalTrials.gov registry record · Phase 4
Insights in Endocervical Mucus Secretion
A Phase 4 study of Cervical Mucus, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT07111247 is a Phase 4 study of Cervical Mucus that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07111247, a Phase 4 study of Cervical Mucus, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.
Conditions Studied
Interventions
- DRUG Gonadotropin Releasing Hormone Antagonists Relugolix
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07111247
The ClinicalTrials.gov registry entry for NCT07111247 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cervical Mucus appearing as the primary indexed condition, and to 1 intervention - of which Gonadotropin Releasing Hormone Antagonists Relugolix is the first listed.
NCT07111247 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT07111247 about?
NCT07111247 is a clinical study titled "Insights in Endocervical Mucus Secretion". Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.
What is the current status of trial NCT07111247?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2026-01-02. Estimated completion is 2027-08.
What conditions does trial NCT07111247 study?
This clinical trial studies the following conditions: Cervical Mucus.
What interventions are being tested in trial NCT07111247?
The interventions under investigation include: Gonadotropin Releasing Hormone Antagonists Relugolix (DRUG).
Who is sponsoring clinical trial NCT07111247?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07111247 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.